CytomX Reports Positive CRC Data for Varseta-M, Aims for FDA Alignment in 2026 — CytomX Therapeutics, Inc.

Event summary

CytomX reported positive Phase 1 data for Varseta-M in advanced colorectal cancer, with FDA alignment discussions targeted for mid-2026.
Company ended 2025 with $137.1M in cash, providing runway into Q2 2027.
Astellas terminated its collaboration with CytomX, effective Q2 2026.
CX-801 combination data with KEYTRUDA expected by year-end 2026.

The big picture

CytomX's progress with Varseta-M underscores its leadership in masked biologics, but the company faces challenges in sustaining revenue growth following the completion of key collaborations. The biotech sector continues to prioritize combination therapies, and CytomX's ability to navigate regulatory pathways will be critical for its long-term success.

What we're watching

Regulatory Pathway: Whether CytomX can secure FDA alignment for a registrational trial design for Varseta-M in late-line CRC by mid-2026.
Pipeline Progress: The pace at which combination studies for Varseta-M and CX-801 advance, particularly with bevacizumab and KEYTRUDA.
Financial Sustainability: How CytomX manages its cash runway amid declining revenues and the termination of the Astellas collaboration.